We compared blonanserin and risperidone for treating Chinese schizophrenia patients.
Patients aged 18–65 years with a PANSS total score of 70–120 were randomized.
Based on a PANSS total score change, blonanserin was as effective as risperidone.
Blonanserin was well tolerated and TEAEs were similar for both groups.
Blonanserin is a useful novel treatment option for Chinese schizophrenia patients.